Publication: Burkholderia pseudomallei acquired ceftazidime resistance due to gene duplication and amplification
Issued Date
2019-05-01
Resource Type
ISSN
18727913
09248579
09248579
Other identifier(s)
2-s2.0-85061932818
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Antimicrobial Agents. Vol.53, No.5 (2019), 582-588
Suggested Citation
Sunisa Chirakul, Nawarat Somprasong, Michael H. Norris, Vanaporn Wuthiekanun, Narisara Chantratita, Apichai Tuanyok, Herbert P. Schweizer Burkholderia pseudomallei acquired ceftazidime resistance due to gene duplication and amplification. International Journal of Antimicrobial Agents. Vol.53, No.5 (2019), 582-588. doi:10.1016/j.ijantimicag.2019.01.003 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/51672
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Burkholderia pseudomallei acquired ceftazidime resistance due to gene duplication and amplification
Other Contributor(s)
Abstract
© 2019 Elsevier Ltd Ceftazidime (CAZ) is the antibiotic of choice for the treatment of Burkholderia pseudomallei infection (melioidosis). The chromosomally-encoded PenA β-lactamase possesses weak cephalosporinase activity. The wild-type penA gene confers clinically significant CAZ resistance only when overexpressed due to a promoter mutation, transcriptional antitermination or by gene duplication and amplification (GDA). Here we characterise a reversible 33-kb GDA event involving wild-type penA in a CAZ-resistant B. pseudomallei clinical isolate from Thailand. We show that duplication arises from exchanges between short (<10 bp) chromosomal sequences, which in this example consist of 4-bp repeats flanked by 3-bp inverted repeats. GDA involving β-lactamases may be a common CAZ resistance mechanism in B. pseudomallei.